Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Travere Therapeutics reported a quarterly loss of $0.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.58, representing an earnings surprise of -25.86% [1] - The company posted revenues of $74.79 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.84%, and showing a significant increase from $45.06 million in the same quarter last year [2] - Travere shares have increased approximately 33.9% since the beginning of the year, outperforming the S&P 500's gain of 4.5% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $70.16 million, and for the current fiscal year, it is -$1.40 on revenues of $345.91 million [7] - The Medical - Biomedical and Genetics industry, to which Travere belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]